Beyond Conventional PRP: A Rationale for Bioengineered, Growth-Factor-Defined Platelet Mimetics in Alopecia—The Precision Re-Engineered Efficacy Optimization Framework

This review covers the diverse clinical applications of platelet-rich plasma in regenerative medicine but provides no new clinical results.

This study found that PRP may increase hair density in breast cancer survivors with EIA or pCIA, but improvements did not differ statistically between treated and untreated sides.

PRP injections can increase hair density in people with androgenic alopecia.

This study observed that combining PRP and Tressfix Serum significantly improved hair regrowth and reduced microRNA expression linked to Chronic Telogen Effluvium compared to using either treatment alone.

This meta-analysis found that PRP monotherapy improved hair density in androgenetic alopecia patients but did not affect hair diameter, with stronger effects observed in male subjects.

This study concluded that platelet-rich plasma is effective and safe for increasing hair density in androgenetic alopecia, showing significant improvement compared to placebo at 3 and 6 months.

This review suggests that platelet-rich plasma may be a promising treatment for immune-mediated alopecias, including alopecia areata and primary cicatricial alopecias, but definitive recommendations are limited due to insufficient high-quality evidence.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This pilot study suggests that platelet-rich plasma may be a promising treatment for chronic telogen effluvium with good safety, and cost-effective preparation methods may be reliable alternatives to more expensive ones.

This review analyzed 17 recent clinical trials on platelet-rich plasma for androgenetic alopecia but reports no new clinical results; the authors seek a consensus on optimal PRP use.

This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.

This study explored the use of "microfollicles," a human hair follicle organoid model, as an in vitro tool for testing hair-growth substances, finding up to 75% overlap in gene expression changes with human clinical biopsy responses to minoxidil, indicating its potential for pre-clinical substance testing.

This review discusses the potential use of platelet-rich plasma for treating alopecia areata but reports no new experimental findings, noting the need for standardized protocols and larger studies to evaluate its efficacy.

This study found that platelet-derived growth factor signaling is crucial for maintaining the hair follicle dermal stem cell pool and supporting their regenerative capacity.

This study found that 3D microtissue models of dermal papilla cells can enhance the ability to induce hair-follicle neogenesis in vivo, offering potential for controlled cell production in follicle regeneration.

This case study reports that combining platelet-rich plasma with intradermal triamcinolone acetonide improved hair regrowth and fiber diameter in one patient with alopecia areata compared to triamcinolone alone.

This study identified mutations in the FGF5 gene as a cause of extreme eyelash growth in Pakistani families, highlighting a potential target for regulating eyelash growth.

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.

This study found that VEGF stimulates the proliferation of human hair follicle dermal papilla cells via the VEGFR-2/ERK pathway, without involving p38, JNK, or AKT signaling.

In this study, IGF-I was shown to enhance human hair follicle growth, maintain the anagen phase, and increase expression of certain growth factors and anti-apoptotic markers.

This study introduced a new classification system for distinguishing between anagen VI and early catagen stages in human hair follicle organ culture, using it to confirm eflornithine's ability to induce premature catagen.

This review discusses the advantages and limitations of various hair loss evaluation methods but reports no new results; it emphasizes the importance of cautious interpretation for these diagnostic tools.

This study found that injecting PDGF-AA and -BB into mouse skin immediately triggered the hair growth cycle's anagen phase, suggesting potential treatment options for certain types of alopecia.

In this study, researchers found that certain cytokines can significantly down-regulate PDGF expression in dermal papilla cells and follicular keratinocytes, indicating a potential link between PDGF signaling and catagen induction.

This study found that VEGF significantly enhances perifollicular vascularization during the hair growth phase, accelerating hair regrowth and increasing follicle and hair size, while its inhibition retards hair growth.

In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.